Adia Nutrition Inc. Divests Biolete Coffee Subsidiary to Cement Factory LLC, Retains 18% Ownership to Support Strategic Focus on Regenerative Medicine and Medical Sales
Adia Nutrition (OTCQB: ADIA) announced the sale of its Biolete coffee subsidiary to Cement Factory LLC on October 6, 2025, while retaining an 18% ownership stake in Cement Factory.
The move shifts Adia's focus to regenerative medicine: plans include tripling its specialized sales force in 2025, expanding Adia Med clinics, and funding R&D for next‑generation therapies. The company also cited a court‑ordered cancellation of over 25 million improperly issued shares to enhance shareholder value. Proceeds from the sale will support medical expansion; investor updates will follow via SEC filings and corporate announcements.
Adia Nutrition (OTCQB: ADIA) ha annunciato la vendita della sua controllata Biolete Coffee a Cement Factory LLC il 6 ottobre 2025, mantenendo una partecipazione del 18% in Cement Factory.
La mossa sposta l'attenzione di Adia verso la medicina rigenerativa: tra i piani c'è triplicare la forza vendita specializzata nel 2025, espandere le cliniche Adia Med e finanziare la ricerca e sviluppo per terapie di prossima generazione. L'azienda ha inoltre citato una cancellazione ordinata dal tribunale di oltre 25 milioni di azioni emesse impropriamente per aumentare il valore per gli azionisti. I proventi della vendita supporteranno l'espansione medica; gli aggiornamenti agli investitori seguiranno tramite procedimenti SEC e comunicati societari.
Adia Nutrition (OTCQB: ADIA) anunció la venta de su subsidiaria Biolete Coffee a Cement Factory LLC el 6 de octubre de 2025, manteniendo una participación del 18% en Cement Factory.
La operación cambia el foco de Adia hacia la medicina regenerativa: entre los planes se incluye triplicar su fuerza de ventas especializada en 2025, ampliar las clínicas Adia Med y financiar I+D para terapias de próxima generación. La empresa también citó una cancelación ordenada por el tribunal de más de 25 millones de acciones emitidas de forma indebida para mejorar el valor para los accionistas. los ingresos de la venta apoyarán la expansión médica; las actualizaciones para los inversionistas seguirán a través de presentaciones ante la SEC y comunicados corporativos.
Adia Nutrition (OTCQB: ADIA)가 2025년 10월 6일 Biolete Coffee 자회사를 Cement Factory LLC에 매각했다고 발표했으며, Cement Factory에 18%의 지분을 보유하게 되었습니다.
이 결정은 Adia의 초점을 재생의학으로 전환합니다: 2025년에 전문 영업력을 3배로 늘리고, Adia Med 클리닉을 확장하며 차세대 치료법을 위한 연구개발을 자금 지원하는 등 계획이 포함됩니다. 회사는 또한 잘못 발행된 주식 2,500만 주 이상에 대한 법원 명령에 의한 취소를 언급하여 주주 가치를 높이고자 합니다. 매각 수익은 의료 확장을 지원할 것이며 투자자 업데이트는 SEC 제출 및 기업 공지를 통해 이어질 예정입니다.
Adia Nutrition (OTCQB: ADIA) a annoncé la vente de sa filiale Biolete Coffee à Cement Factory LLC le 6 octobre 2025, tout en conservant une participation de 18% dans Cement Factory.
Cette démarche oriente Adia vers la médecine régénérative: les plans incluent un triplement de sa force de vente spécialisée en 2025, l'expansion des cliniques Adia Med et le financement de la R&D pour des thérapies de prochaine génération. L'entreprise a également évoqué une annulation ordonnée par le tribunal de plus de 25 millions d'actions émises indûment afin d'améliorer la valeur pour les actionnaires. Les produits de la vente soutiendront l'expansion médicale; les mises à jour destinées aux investisseurs suivront via les dépôts SEC et les communiqués d'entreprise.
Adia Nutrition (OTCQB: ADIA) kündigte den Verkauf ihrer Biolete Coffee-Tochter an Cement Factory LLC am 6. Oktober 2025 an, während eine 18%-Beteiligung an Cement Factory beibehalten wird.
Der Schritt verlagert Adias Fokus auf die regenerative Medizin: Zu den Plänen gehört, die spezialisierte Vertriebsbelegschaft im Jahr 2025 zu verdoppeln/ein Drittel zu verdreifachen, Adia Med-Kliniken auszubauen und F&E für Therapien der nächsten Generation zu finanzieren. Das Unternehmen verwies zudem auf eine gerichtlich angeordnete Stornierung von über 25 Millionen unrechtmäßig ausgegebener Aktien, um den Wert für die Aktionäre zu erhöhen. Die Erlöse aus dem Verkauf sollen die medizinische Expansion unterstützen; Investoren-Updates erfolgen über SEC-Einreichungen und Unternehmensankündigungen.
Adia Nutrition (OTCQB: ADIA) أعلنت عن بيع فرعها Biolete Coffee إلى شركة Cement Factory LLC في 6 أكتوبر 2025، مع الاحتفاظ بحصة بنسبة 18% في Cement Factory.
توجّه هذه الخطوة تركيز Adia نحو الطب التجديدي: من بين الخطط مضاعفة قوة المبيعات المتخصصة في 2025، توسيع عيادات Adia Med، وتمويل البحث والتطوير لعلاجات الجيل القادم. كما أشارت الشركة إلى إلغاء أمر قضائي لأكثر من 25 مليون سهم تم إصدارها بشكل غير صحيح بهدف تعزيز قيمة المساهمين. ستدعم عوائد البيع التوسع الطبي؛ وستتابع تحديثات المستثمرين عبر ملفات SEC وإعلانات الشركات.
Adia Nutrition (OTCQB: ADIA) 于 2025 年 10 月 6 日宣布将其 Biolete Coffee 子公司出售给 Cement Factory LLC，同时在 Cement Factory 持有 18% 的股权。
这一举措将 Adia 的重点转向再生医学：计划在 2025 年将其专业销售团队扩展三倍，扩大 Adia Med 诊所，并为下一代疗法的研发提供资金。公司还提到了一项 法院命令取消了超过 2500 万股错误发行的股份，以提升股东价值。出售所得将用于支持医疗扩张；投资者更新将通过 SEC 文件和公司公告进行。
- Retains 18% ownership in Biolete via Cement Factory LLC
- Proceeds earmarked to expand Adia Med clinics and R&D
- Sales force tripled in 2025 to drive regenerative product adoption
- 25M+ shares canceled by court order to improve shareholder transparency
- Divestiture ends direct consumer‑brand ownership, reducing portfolio diversification
- Retaining 18% stake limits operational control over Biolete's future decisions
Winter Park, Florida--(Newsfile Corp. - October 6, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), an emerging leader in regenerative medicine and innovative healthcare solutions, today announced the sale of its Biolete coffee subsidiary to Cement Factory LLC, a dynamic consumer products firm led by key owners Jeff Sciullo and AJ Sims. Adia will retain an
Biolete Coffee
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/269272_pouringaservingofbiolete_cafelatte-cropped.jpg
The transaction transfers full operational control of Biolete-a pioneer in organic protein and mushroom-infused coffee products acquired by Adia in July 2024-to Cement Factory LLC. Originally integrated to diversify Adia's wellness portfolio, Biolete has grown significantly, expanding to platforms like Amazon and cultivating a loyal customer base for its collagen-boosted, functional beverages. Sciullo and Sims, seasoned entrepreneurs with expertise in scaling consumer brands, are well-positioned to drive Biolete's next chapter of innovation and market expansion, while Adia's
"This divestiture sharpens our focus on delivering transformative medical treatments and regenerative therapies, areas where we see unparalleled growth potential," said Larry Powalisz, CEO of Adia Nutrition Inc. "By retaining an
"Adia's strategic pivot builds on a series of milestones in its medical division. In 2025, Adia tripled its sales force with dedicated regional teams to drive U.S. and global adoption of AdiaLabs' premier regenerative products, including AdiaVita and AdiaLink. Earlier this year, the company opened its first satellite clinic, expanding access to regenerative treatments and reinforcing its commitment to community-based care. Additionally, Adia strengthened its corporate governance by securing a court-ordered cancellation of over 25 million improperly issued shares, enhancing shareholder value and operational transparency.
"We're thrilled to acquire Biolete and build on its reputation for innovative, health-focused beverages," said Jeff Sciullo, Co-Owner of Cement Factory LLC. "With Adia as a strategic partner holding an
AJ Sims, Co-Owner of Cement Factory LLC, added, "Biolete's unique formulations are a perfect fit for our expertise in premium supplement products. We look forward to accelerating its e-commerce presence and investing in R&D to reach a broader audience."
Proceeds from the sale will fuel Adia's medical expansion, including the development of additional Adia Med clinics and enhanced R&D for next-generation therapies. The company's
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269272
FAQ
What did Adia Nutrition (ADIA) announce on October 6, 2025 about Biolete?
How will the Biolete sale affect Adia Nutrition's (ADIA) business focus?
Does Adia Nutrition (ADIA) keep any ownership in Biolete after the sale?
What corporate governance change did Adia Nutrition (ADIA) report alongside the sale?
Will Adia Nutrition (ADIA) provide further financial details about the Biolete transaction?
